Compare Stocks: TAOX, UNCY, RFAI, and NMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMRA Neumora Therapeutics	$0.73 -0.7%	$1.40	$0.68 ▼ $3.65	$136.23M	2.71	1.67 million shs	164,471 shs
RFAI RF Acquisition Corp II	$34.02 -0.6%	$25.60	$8.94 ▼ $73.00	$119.41M	1.16	62,481 shs	1,255 shs
TAOX Synaptogenix	$4.32 +0.0%	$3.74	$3.07 ▼ $10.00	$32.32M	1.49	156,290 shs	58,280 shs
UNCY Unicycive Therapeutics	$4.71 -2.2%	$5.21	$3.71 ▼ $8.74	$131.03M	1.79	919,310 shs	101,455 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMRA Neumora Therapeutics	-6.06%	-5.03%	-52.05%	-51.57%	-61.71%
RFAI RF Acquisition Corp II	-6.70%	-11.38%	-32.95%	+210.08%	+221.62%
TAOX Synaptogenix	-3.79%	+16.76%	+10.49%	+27.43%	-24.08%
UNCY Unicycive Therapeutics	-3.02%	+0.63%	-9.93%	-41.41%	+20.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMRA Neumora Therapeutics	$0.73 -0.7%	$1.40	$0.68 ▼ $3.65	$136.23M	2.71	1.67 million shs	164,471 shs
RFAI RF Acquisition Corp II	$34.02 -0.6%	$25.60	$8.94 ▼ $73.00	$119.41M	1.16	62,481 shs	1,255 shs
TAOX Synaptogenix	$4.32 +0.0%	$3.74	$3.07 ▼ $10.00	$32.32M	1.49	156,290 shs	58,280 shs
UNCY Unicycive Therapeutics	$4.71 -2.2%	$5.21	$3.71 ▼ $8.74	$131.03M	1.79	919,310 shs	101,455 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMRA Neumora Therapeutics	-6.06%	-5.03%	-52.05%	-51.57%	-61.71%
RFAI RF Acquisition Corp II	-6.70%	-11.38%	-32.95%	+210.08%	+221.62%
TAOX Synaptogenix	-3.79%	+16.76%	+10.49%	+27.43%	-24.08%
UNCY Unicycive Therapeutics	-3.02%	+0.63%	-9.93%	-41.41%	+20.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	805.16% Upside
RFAI RF Acquisition Corp II	1.00	Sell	N/A	N/A
TAOX Synaptogenix	1.00	Sell	N/A	N/A
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.75	298.51% Upside

Current Analyst Ratings Breakdown

Latest TAOX, UNCY, RFAI, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00 ➝ $25.00
8/12/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00 ➝ $20.00
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	$300K	107.74	N/A	N/A	$2.83 per share	1.53
UNCY Unicycive Therapeutics	$680K	192.70	N/A	N/A	$1.41 per share	3.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	-$28.74M	-$3.85	N/A	N/A	N/A	-2,153.97%	-128.51%	-97.54%	N/A
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	2.18	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)

Latest TAOX, UNCY, RFAI, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	TAOX Synaptogenix	N/A	-$1.83	N/A	-$1.83	N/A	$0.09 million
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NMRA Neumora Therapeutics	1.19	4.50	4.50
RFAI RF Acquisition Corp II	N/A	N/A	N/A
TAOX Synaptogenix	N/A	19.98	19.98
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NMRA Neumora Therapeutics	47.65%
RFAI RF Acquisition Corp II	N/A
TAOX Synaptogenix	10.34%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
NMRA Neumora Therapeutics	26.94%
RFAI RF Acquisition Corp II	39.10%
TAOX Synaptogenix	2.70%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
RFAI RF Acquisition Corp II	2	3.51 million	2.14 million	N/A
TAOX Synaptogenix	4	7.48 million	7.28 million	N/A
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Not Optionable

TAOX, UNCY, RFAI, and NMRA Headlines

Recent News About These Companies

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt

38 minutes ago | prnewswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

September 24 at 3:54 AM | prnewswire.com

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

September 23 at 1:45 PM | theglobeandmail.com

UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

September 23 at 10:09 AM | prnewswire.com

Kaplan Fox Announces a Securities Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - Lead Plaintiff Deadline is November 2, 2026

September 23 at 7:40 AM | newsfilecorp.comN

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 22 at 7:33 PM | globenewswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 22 at 6:31 PM | newsfilecorp.comN

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

September 22 at 5:08 PM | newsfilecorp.comN

UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

September 22 at 11:11 AM | globenewswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 22 at 10:02 AM | globenewswire.com

UNCY stock rises after a class action filing and a reverse split

September 21 at 7:04 PM | ad-hoc-news.deA

ROSEN, A TOP-RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 21 at 6:26 PM | newsfilecorp.comN

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 21 at 2:10 PM | globenewswire.com

Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) with Significant Losses to a Securities Class Action Deadline on November 2, 2026

September 21 at 9:55 AM | newsfilecorp.comN

Financial Survey: Phathom Pharmaceuticals (NASDAQ:PHAT) versus Unicycive Therapeutics (NASDAQ:UNCY)

September 21 at 8:45 AM | americanbankingnews.com

Unicycive Therapeutics stock holds at USD 4.80

September 20, 2026 | ad-hoc-news.deA

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

September 20, 2026 | newsfilecorp.comN

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

September 18, 2026 | businesswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

September 18, 2026 | prnewswire.com

ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 18, 2026 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX, UNCY, RFAI, and NMRA Company Descriptions

Neumora Therapeutics NASDAQ:NMRA

$0.73 -0.01 (-0.72%)

As of 10:48 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

RF Acquisition Corp II NASDAQ:RFAI

$34.02 -0.20 (-0.58%)

As of 10:47 AM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Synaptogenix NASDAQ:TAOX

$4.32 +0.00 (+0.02%)

As of 10:45 AM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Unicycive Therapeutics NASDAQ:UNCY

$4.70 -0.11 (-2.18%)

As of 10:48 AM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAOX, UNCY, RFAI, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAOX, UNCY, RFAI, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TAOX, UNCY, RFAI, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX, UNCY, RFAI, and NMRA Company Descriptions

Neumora Therapeutics NASDAQ:NMRA

RF Acquisition Corp II NASDAQ:RFAI

Synaptogenix NASDAQ:TAOX

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TAOX, UNCY, RFAI, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TAOX, UNCY, RFAI, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TAOX, UNCY, RFAI, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX, UNCY, RFAI, and NMRA Company Descriptions

Neumora Therapeutics NASDAQ:NMRA

RF Acquisition Corp II NASDAQ:RFAI

Synaptogenix NASDAQ:TAOX

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools